Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

EVOTEC AG (EVT)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Evotec : to Attend Upcoming Investor Conferences

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/14/2017 | 06:38pm CEST

By a News Reporter-Staff News Editor at Biotech Week -- Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced that its management will be presenting at the Morgan Stanley 15th Annual Global Healthcare Conference in New York, USA; 6th German Corporate Conference, Berenberg/Goldman Sachs in Munich, Germany, and Baader Investment Conference, Munich, Germany, and will be attending Goldman Sachs' 7th Annual Biotech Symposium in London, UK, and Bank of America Merrill Lynch Global Healthcare Conference 2017 in London ,UK. Goldman Sachs' 7th Annual Biotech Symposium, London, UK - Date: Friday, 08 September 2017

- Venue: London, UK

- Attendee: Enno Spillner, Chief Financial Officer of Evotec AG Morgan Stanley 15th Annual Global Healthcare Conference, New York, USA - Date: Monday, 11 September 2017, 04.50 pm EDT (09.50 pm BST, 10.50 pm CEST)

- Venue: New York, NY, USA

- Attendee: Dr Werner Lanthaler, Chief Executive Officer of Evotec AG Bank of America Merrill Lynch Global Healthcare Conference 2017, London, UK - Date: Thursday, 14 September 2017

- Venue: London, UK

- Attendee: Enno Spillner, Chief Financial Officer of Evotec AG 6th German Corporate Conference, Berenberg/Goldman Sachs, Munich, Germany - Date: Monday, 18 September 2017, 11.00 am CEST (10.00 am BST, 05.00 am EDT)

- Venue: Munich, Germany

- Attendee: Enno Spillner, Chief Financial Officer of Evotec AG Baader Investment Conference, Munich, Germany - Date: Wednesday, 20 September 2017, 05.15 pm CEST (04.15 am BST, 11.15 am EDT)

- Venue: Munich, Germany

Keywords for this news article include: Biotechnology, Evotec AG (see also Evotec AG).

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EVOTEC AG
10/19 EVOTEC : Achieves First Milestone in Neurodegeneration Alliance with Celgene
10/12 EVOTEC : achieves first milestone in neurodegeneration alliance with Celgene
10/10 EVOTEC : Achieves First Milestone in Neurodegeneration Alliance with Celgene
10/10 EVOTEC : Achieves first milestone in neurodegeneration alliance with celgene
10/02 EVOTEC : invests in Exscientia to advance AI-driven drug discovery
09/29 EVOTEC AG : Release according to Article 26a of the WpHG [the German Securities ..
09/28 EVOTEC : Invests in Exscientia to Advance AI-Driven Drug Discovery
09/28 EVOTEC : Invests in exscientia to advance ai-driven drug discovery
09/21 EVOTEC : and MaRS Innovation Establish Academic Bridge 'LAB150' in Toronto
09/18 EVOTEC AG : Notification and public disclosure of transactions by persons
More news
News from SeekingAlpha
10/20 Evotec short pitch at Robin Hood conference; shares fall 4%
09/28 Evotec invests in Exscientia to advance AI-driven drug discovery
08/10 Evotec's (EVOTF) CEO Werner Lanthaler on Q2 2017 Results - Earnings Call Tran..
08/10 Evotec AG 2017 Q2 - Results - Earnings Call Slides
08/10 Evotec AG reports Q2 results
Financials (€)
Sales 2017 232 M
EBIT 2017 40,9 M
Net income 2017 26,8 M
Debt 2017 10,9 M
Yield 2017 -
P/E ratio 2017 104,25
P/E ratio 2018 72,17
EV / Sales 2017 12,0x
EV / Sales 2018 8,87x
Capitalization 2 768 M
Chart EVOTEC AG
Duration : Period :
Evotec AG Technical Analysis Chart | EVT | DE0005664809 | 4-Traders
Technical analysis trends EVOTEC AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Average target price 13,2 €
Spread / Average Target -30%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Mario Polywka Chief Operating Officer
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC AG192.93%3 261
INCYTE CORPORATION13.96%24 054
QUINTILES IMS HOLDINGS INC33.89%22 162
LONZA GROUP59.15%19 392
CELLTRION, INC.--.--%19 297
ALNYLAM PHARMACEUTICALS, INC.208.84%10 522